Canadian-based biotechnology company NoNO has begun the Phase III clinical trial (ESCAPE-NA-1) of NA-1 for the treatment of patients with acute ischemic stroke (AIS).

A part of the class of PSD-95 inhibitors, NA-1 is being developed to disrupt pro-death signalling pathways that involve postsynaptic density-95 (PSD-95) protein.

The multicentre, randomised, double-blinded, placebo-controlled, parallel group, single-dose Phase III trial will evaluate the efficacy and safety of the intravenous NA-1 for reducing functional disability in AIS patients undergoing endovascular thrombectomy.

ESCAPE-NA-1 study is being conducted in collaboration with the University of Calgary Stroke Unit.

NoNO president and chief executive officer Michael Tymianski said: “For the first time, neuroprotection will be evaluated in a clinical setting of ischemia-reperfusion, in which neuroprotection has the largest treatment effect.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“For the first time, neuroprotection will be evaluated in a clinical setting of ischemia-reperfusion, in which neuroprotection has the largest treatment effect.”

“ESCAPE-NA-1 addresses the deficiencies of past neuroprotection trials as it is the first study to have a design grounded in and consistent with the preclinical science, to minimise subject heterogeneity, to ensure that the treatment effect size is maximised, and to enrol subjects in the correct therapeutic window.”

The Phase III trial is based on the positive results from a clinical trial ESCAPE conducted by the University of Calgary.

NA-1 has reportedly demonstrated positive outcomes in Phase I and II clinical trials conducted in the US and Canada.

It is being further evaluated in another Phase III FRONTIER trial.

NoNO focuses on developing therapeutic agents that inhibit protein-protein interactions in cellular signals, to treat diseases associated with the nervous system, stroke, traumatic brain injury and neuropathic pain.